Latest News & Publications

Media Center

Connect with us and get the latest news on how AsclepiX Therapeutics is working to develop life-transforming medicines to make hope a reality for patients in need

Latest News

June 24, 2020 in News

AsclepiX Therapeutics Announces $35 Million Series A Financing

Proceeds to fund development of AXT107 for treatment of retinal diseases through Phase 1/2a clinical trials Series A financing led by the Perceptive Xontogeny Venture Fund BALTIMORE, MD, June 24,…
Read More
January 6, 2020 in News

AsclepiX Therapeutics, Inc. Expands Leadership Team with Appointment of Industry Leader Theresa Heah, MD, MBA as Chief Medical Officer.

Monday, January 6, 2020 8:00 AM BALTIMORE, MD – AsclepiX Therapeutics, Inc., a biopharmaceutical company that uses computational biology to identify potent peptide regulators of vascular and cellular homeostasis for…
Read More
November 13, 2019 in News

AsclepiX Therapeutics Raises $5M in New Funding. Financing will advance clinical development of the Company’s lead product AXT107.

Financing will advance clinical development of the Company’s lead product AXT107 BALTIMORE – AsclepiX Therapeutics, Inc., a biopharmaceutical company focused on developing vital new therapies based on a novel peptide…
Read More
July 16, 2019 in News

AsclepiX Therapeutics Selected to Present at Ophthalmology Innovation Summit (OIS) at the American Society for Retinal Surgeons (ASRS) Annual Conference.

BALTIMORE, MD / ACCESSWIRE / July 16, 2019 / AsclepiX Therapeutics, Inc., a biopharmaceutical company focused on the use of artificial intelligence (AI) to discover, design, develop, and deliver novel…
Read More
March 25, 2019 in News

AsclepiX Therapeutics, Inc. Strengthens Board of Directors, Welcomes Steven M. Altschuler, MD

BALTIMORE, MD – AsclepiX Therapeutics, Inc, a biopharmaceutical company focused on developing vital new therapies based on a novel collagen IV-derived peptide called AXT107, announces that Steven Altschuler, MD has…
Read More
March 18, 2019 in News

AXT107 Restores Healthy, Non-Leaky Vasculature in the Eye by Inhibiting VEGFR2 and Activating Tie2, the Two Clinically Validated Pathways in Diseases of the Retina.

BALTIMORE, MD – AsclepiX Therapeutics, Inc., a biopharmaceutical company focused on developing vital new peptide therapies, including a novel collagen IV-derived peptide called AXT107, announces the publication of a study…
Read More

Scientific Publications

AXT107 Publications

AXT201 Publications

AXT301 & AXT501 Publications